trending Market Intelligence /marketintelligence/en/news-insights/trending/vmshv9l4tg2gywwl_m-cwa2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Akers Biosciences gets notice from Nasdaq for listing rule violation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Akers Biosciences gets notice from Nasdaq for listing rule violation

The Akers Biosciences Inc. said it received a notice from the Nasdaq Stock Market for failure to comply with one of the listing rules.

The Thorofare, N.J.-based healthcare company violated the Nasdaq's shareholder approval requirement with its 2013 incentive stock and award plan, from before its IPO on Nasdaq. Akers Biosciences' board had amended and upsized the plan twice, in 2015 and in 2016. The company became aware of the potential violation in the first quarter of 2018 and notified Nasdaq.

Akers Biosciences has until June 25 to submit a plan to regain compliance and then 180 calendar days to implement it, if approved. The notice has no current effect on the company's Nasdaq listing.

Recently, Akers said it was granted additional time to comply with Nasdaq's $1 per share minimum bid price requirement.

Akers develops and manufactures rapid screening and testing products.